The absence of 4E-BP1 and 4E-BP2 in pancreatic cancer cells prevents G1 phase inhibition by mTOR inhibitors owing to a less effective repression of general protein synthesis and, more specifically, to a lack in the repression of cyclin D1 post-transcriptional expression [4]. Here, MTOR is linked to pancreatic neoplasm.